Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Civelestat sodium for sepsis-associated mild to moderate ARDS
ChiCTR2200056892Phase 4Not yet recruiting
- Sponsor
- Liaocheng City People's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sivelestat in sepsis and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Liaocheng City People's Hospital. Primary endpoints: Oxygenation index, Mode and time of breathing support and 1 more. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
sepsisacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2200056892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056892.